- Polomar Health Services, Inc. (PMHS) executed an **Amended and Restated Product Fulfillment and Distribution Agreement** with ForHumanity, Inc. and Island Group 40, LLC, effective **August 19, 2025**.  **[1265521_0001641172-25-025989_form8-k.htm:0]** **[1265521_0001641172-25-025989_ex10-1.htm:8]** 
- The agreement grants ForHumanity **exclusive marketing rights** for PMHS's previously licensed, patent-pending inhalable sildenafil and inhalable eletriptan, with PMHS's wholly-owned subsidiary responsible for fulfilling prescriptions.  **[1265521_0001641172-25-025989_form8-k.htm:0]** 
- The initial term of the Amended Agreement is **42 months**, commencing **March 17, 2025**, and terminating **September 16, 2028**.  **[1265521_0001641172-25-025989_form8-k.htm:0]** **[1265521_0001641172-25-025989_ex10-1.htm:0]** 
- ForHumanity's exclusivity to market the products is granted through **March 31, 2026**, in exchange for guaranteed payments of **$750,000**, of which **$200,000** has been received by PMHS.  **[1265521_0001641172-25-025989_form8-k.htm:1]** **[1265521_0001641172-25-025989_ex10-1.htm:2]** 
- Exclusivity may be extended through **September 30, 2026**, if ForHumanity remits a minimum of **$1,500,000** in sales revenue to PMHS prior to **March 31, 2026**, and can be maintained through **December 31, 2026**, if PMHS receives at least **$3,000,000** in revenue prior to **June 30, 2026**.  **[1265521_0001641172-25-025989_form8-k.htm:1]** **[1265521_0001641172-25-025989_ex10-1.htm:2]**

Polomar Health Services (PMHS)